

Kicket Alexandre State Alexand

Genetic Markers Could Help Identify Hospital Patients at Risk for AKI

By Kurtis Pivert

clues about the pathogenesis of AKI. The findings could eventually lead to potential therapeutic interventions to help prevent kidney failure and premature death in thousands of patients who undergo cardiovascular surgery or other hospital interventions each year. Currently, AKI affects one in five hospitalized patients worldwide.

Collaborators from Yale University, Vanderbilt University, and the University of Western Ontario wanted to determine if they could identify patients who may have a higher ge-

netic risk for developing AKI in the hospital. Doing so could uncover novel pathways that could be targeted for therapeutic interventions, said senior author Chirag R. Parikh, MD, PhD, FASN of Yale.

Investigators in this multicenter

study weren't alone in their clinical suspicion that some individuals could have a genetic predisposition for developing AKI in the hospital setting. "What is clear is that patients of similar age and health status can have drastically different kidney outcomes after a potential insult like cardiopulmonary bypass surgery," said Benjamin Humphreys, MD, PhD, FASN, of Brigham and Women's Hospital and Director of the Harvard Stem Cell Institute Kidney Group in Boston. "Many patients do just fine, but others develop AKI. The absence of obvious clinical factors to explain these divergent outcomes suggests a role for genetic predisposition.'

Until recently, analysis methods limited the scope of genetic AKI studies. "The putative genetic components of AKI have until recent years been mainly investigated by hypothesis-driven research (of candidate genes)," Parikh said. "But technological progress in genotyping has opened the possibilities

Continued on page 3

Most Americans Aren't Healthy Enough to Be Kidney Donors

Just over half of adults in the United States—including nearly two-thirds of African Americans—have health conditions that would preclude their becoming living kidney donors, according to a study presented at Kidney Week 2014.

esearchers have isolated sev-

eral genetic markers that could

help identify individuals at risk

for acute kidney injury (AKI) in the

hospital setting (1). Results from the

study presented at ASN Kidney Week

2014 in Philadelphia, PA, offer new

Anthony J. Bleyer, Jr., and colleagues of Wake Forest School of Medicine, Winston-Salem, NC, performed a population-based study to estimate the percentage of Americans healthy enough for kidney donation. The analysis included data on adults aged 21 to 70 years, drawn from The National Health and Nutrition Examination Survey 2010–2011. The investigators studied the presence of common factors that are used to exclude volunteers from donating a kidney in a representative sample of the United States population.

They found that 55.2 percent of the United States population would be ineligible to donate a kidney because of health conditions. A history of hypertension, the most common excluding condition, was present in 19.2 percent of participants. This was followed by obesity, 15.0 percent; excessive alcohol intake (more than four drinks per day), 11.6 percent; and diabetes, 11.5 percent.

Inside

Kidney Week 2014

Top findings in AKI clinical trials; how exercise, diet and air pollution affect kidney health; and Americans' growing ineligibility to donate kidneys

Journal View

CKD patients at risk for excessive bleeding from dabigatran for atrial fibrillation versus warfarin


Policy Update

No CMS surprises in store for kidney sphere in 2015; ASN visits to NIH and Patient-Centered Outcomes Research Institute pay dividends; and ASN recaps 2014 efforts to address health disparities

Ebola

Dialysis can play a key role in survival for patients with Ebola virus disease. Read about the latest updates in kidney professionals' role in patient care, and learn more from a wealth of ASN and CDC resources








HeRO Graft Candidates

- Catheter-dependent or approaching catheterdependency
- Failing AVF or AVG due to central venous stenosis

Treatment Algorithm





infection rate compared with

a 16% to 32% improvement compared

cumulative patency at 2 years^{1, 2}

per year compared with catheters³

catheters¹

with catheters¹

HeRO Graft

Catheter-dependent patients

Graft

Catheter

Learn more at www.herograft.com Order at: 888.427.9654

References:

1) Katzman et al., J Vasc Surg 2009. 2) Gage et al., EJVES 2012. 3) Dageforde et al., JSR 2012. Indications for Use: The HeRO Graft is indicated for end stage renal disease patients on hemodialysis who have exhausted all other access options. See Instructions for Use for full indication, contraindication and caution statements. Rx only.

HeRO Graft is classified by the FDA as a vascular graft prosthesis.

1655 Roberts Boulevard, NW • Kennesaw, Georgia 30144 • Phone (888) 427-9654 • (770) 419-3355 All trademarks are owned by CryoLife, Inc. or its subsidiaries. HeRO Graft is a Hemosphere, Inc. product distributed by CryoLife, Inc. and Hemosphere, Inc. © 2012 CryoLife, Inc. All rights reserved.



1. Download the App 2. Scan the code with your mobile device to watch video

Get the free mobile app at http://gettag.mobi



Kidney Donors

Continued from page 1

The rates of medical ineligibility were higher at lower levels of household income: 60.1 percent of individuals with an income below \$35,000 would be unable to donate, versus 49.3 percent with an income above \$100,000.

Financial pressures and immigration status are nonmedical factors that often affect the ability to be a kidney donor. With the addition of income below the poverty line and non–United States citizenship, 68.5 percent of the United States population would be ineligible to donate. The figure rose to 75.8 percent after the exclusion of smokers and of individuals with shortness of breath when walking up an incline.

There were significant racial and ethnic differences in the distribution of exclusionary medical conditions, with African Americans having the highest rates of obesity, hypertension, diabetes, and microalbuminuria. Overall, 63.9 percent of African Americans would be ineligible to donate, compared with 54.8 percent of whites.

There is a well-recognized shortage of living kidney donors in the United States. The new report is the first population-based study to evaluate the rates of specific medical conditions and social factors that would exclude individuals from living kidney donation.

"It is well known that African Americans and individuals with lower incomes are at an increased risk of kidney failure. Unfortunately, their potential donors—who are very likely to come from the same social groups—are also much less likely to be kidney donors due to comorbid conditions," said Anthony Bleyer, the senior investigator in the study. "Increasing the number of living donors will require addressing this important issue."

Increasing obesity and worsening health of the general population decrease the pool of potential donors. "Financial compensation for time lost at work and lost income would likely improve the ability to donate in 36.1 percent of the eligible donor pool that has an adjusted family household income of less than \$35,000," Bleyer said.



Passing the Torch

By Pascale H. Lane



Six years ago ASN Kidney News did not exist. The magazine came to life in January 2009. Over the years it has grown and developed, much like a child. Despite some early stumbles and falls, it has now learned to walk and talk and live.

As with my own children, ASN Kidney News has matured and readied itself to live without me. I know our new editorin-chief, Richard Lafayette, MD, FACP, will help it mature further; however, I will miss my

baby just the same. I have learned so much from this job, and it has provided me hours of joy (and some frustration) over the past six years.

This swan song would be incomplete without expressing my thanks to a number of people. First, the editorial advisory board provided inspiration and ideas for content and features. Next, I must thank those who wrote and edited articles and feature sections. I know many of you performed these tasks at least somewhat reluctantly, but your efforts made the magazine successful. I must thank the executive editor, Dawn McCoy. She will be continuing in her role, but I will miss our calls. I must also thank *Kidney News* designer Lisa Cain, who conceived the magazine's original design and continues to work wonders with each monthly issue.

Finally, I want to encourage all members of the American Society of Nephrology to get involved in its efforts. The organization does a lot for us, but it needs the input and energy of its members to get it right. Volunteer for a group or committee. Sign up for political action alerts. And always read *ASN Kidney News*.

Pascale H. Lane, MD, FASN, is the outgoing editor-in-chief of ASN Kidney News. She will remain on the KN Editorial Advisory Board.

Genetic Markers

Continued from page 1

toward hypothesis-generating genomic screens and novel opportunities to explore polygenetic perspectives, now spanning a wide array of possible analyses falling under the term Genome-Wide Association Study (GWAS)."

With GWAS scientists can analyze genetic variants in multiple individuals to determine if a disease or trait is linked to any single-nucleotide polymorphisms (SNPs). The method has been utilized to investigate numerous disease conditions from chronic kidney disease to cardiovascular disease to cancer. According to Parikh, it provides an excellent approach to discover genetic factors in a population because of the high number of recombinant events the population represents. Using GWAS methods, the investigators analyzed data from patients at risk for AKI in the hospital setting—760 adults with AKI and 669 adult controls who underwent surgery or received care in the intensive care unit (ICU)—to determine if any SNPs were associated with the development of AKI. The study population was selected from the surgical ICU (TRIBE-AKI study) and the medical ICU (VALID ICU cohort). AKI was defined as a rise in creatinine of 0.3 mg/dL or 50 percent from baseline for at least two days.

After genotyping a total of 992,895 SNPs, the researchers identified six clusters of three or more SNPs on six different chromosomes that are associated with a patient's risk of developing AKI. Among these clusters, four (SOX2-OT, IL33, RAB20, and TAOK1) are intronic (not coding information for protein synthesis) and the remaining 2 are intergenic (involving more than one gene). "All six SNP clusters are protective against AKI, with odds ratios ranging from 0.55 to 0.72," said Parikh.

Brigham and Women's Humphreys found the results very intriguing and noted that they could certainly lead to a better understanding of AKI pathophysiology. "Most of the SNP clusters identified appear to protect against AKI," he said. "Understanding how certain gene variants confer renal protection could lead to new therapeutic strategies as well as new risk prediction tools."

"AKI is a heterogeneous disease and genetic studies need to be continued to fully capture the host risk," Dr. Parikh emphasized. "It is recommended that sequencing can be used as a complement to GWAS, to obtain a better map of the genetic variants in GWAS-significant genes or well-established candidate genes." Although it was a relatively small study by GWAS standards, the results are promising, Humphreys said. "They clearly call for a much larger analysis to rigorously evaluate the association of these candidate SNPs with risk of AKI."

Parikh agreed, adding that "further collaborative research is required utilizing larger cohorts to confirm these findings and identify candidate genes that are mechanistically linked to pathogenesis of AKI."

This study was supported by the National Institutes of Health R01HL085757 and P30 DK079310 O'Brien Kidney Center Grant.

Reference

 Zhao B, et al. Genome-Wide Association Study to Identify Single Nucleotide Polymorphisms Conferring Risk for Acute Kidney Injury. J Am Soc Nephrol 25 (Suppl); 2014:7A.



KidneyNews

Editorial Staff Editor-in-Chief: Pascale H. Lane, MD, FASN Executive Editor: Dawn McCoy Content and Media Analyst: Kurtis Pivert Design: Lisa Cain Design Communications Assistant: Sara Leeds

Editorial Board:

Matthew D. Breyer, MD, FASN, Eli Lilly and Company
Wendy Weinstock Brown, MD, Jesse Brown VA Medical Center, Northwestern University Feinberg School of Medicine, University of Illinois at Chicago
Teri Browne, PhD, MSW, University of South Carolina
Stephen Darrow, MD, University of Minnesota Medical Center
Ira Davis, MD, Baxter Healthcare Corp.
Nishank Jain, MD, MPH (fellow), University of Texas Southwestern Medical Center
Caroline Jennette Poulton, MSW, University of North Carolina Kidney Center
Richard Lafayette, MD, Stanford University Medical Center
Edgar V. Lerma, MD, FASN, University of Ullinois – Chicago /Associates in Nephrology, SC
Teri J. Mauch, MD, FASN, University of Virginia
Matthew A. Sparks, MD, Duke University Hospital
Titte R. Srinivas, MD, Medical University of South Carolina

Advertising Sales:

The Walchli Tauber Group 2225 Old Emmorton Road, Suite 201, Bel Air, MD 21015 443-252-0571 Mobile 443-512-8899 *115 Phone christine.kenney@wt-group.com

ASN Council:

President: Jonathan Himmelfarb, MD, FASN President-elect: Raymond C. Harris, MD, FASN Past-President: Sharon M. Moe, MD, FASN Secretary-Treasurer: John R. Sedor, MD, FASN Communications Committee Chair: Eleanor D. Lederer, MD, FASN Councilors: Eleanor D. Lederer, MD, FASN, Mark D. Okusa, MD, FASN, Mark E. Rosenberg, MD, FASN, Anupam Agarwal, MD, FASN

Executive Director: Tod Ibrahim Director of Communications: Robert Henkel

ASN Kidney News is published by the American Society of Nephrology 1510 H Street NW, Suite 800, Washington, DC 20005. Phone: 202-640-4660

www.asn-online.org

ASN Kidney News is the authoritative source for analysis of trends in medicine, industry, and policy affecting all practitioners in nephrology. The statements and opinions expressed in ASN Kidney News are solely those of the authors and not of the American Society of Nephrology (ASN) or the editorial policy of the editors. The appearance of advertisements in ASN Kidney News is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. The American Society of Nephrology disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

The American Society of Nephrology is organized and operated exclusively for scientific and educational purposes, including enhancing the field of nephrology by advancing the scientific knowledge and clinical practice of that discipline through stimulation of basic and clinical investigation, providing access to new knowledge through the publication of journals and the holding of scientific meetings, advocating for the development of national health policies to improve the quality of care for renal patients, cooperating with other national and international societies and organizations involved in the field of nephrology, and using other means as directed by the Council of the Society.

Postmaster: Please send address changes to *ASN Kidney News*, c/o Customer Service, American Society of Nephrology 1510 H Street NW, Suite 800, Washington, DC 20005.

Publications mail agreement No. 40624074. Return undeliverable Canadian addresses to PO Box 503, RPO West Beaver Creek, Richmond Hill ON L4B 4R6

ASN Kidney News (ISSN print 1943-8044 and online 1943-8052) is an official publication of the American Society of Nephrology, 1510 H Street NW #800, Washington DC 20005, and is published monthly. Periodicals postage paid at Washington, DC and at additional mailing offices. Subscription rates: \$12 per year. To order, please email bhenkel@asn-online.org. Subscription prices subject to change. Annual ASN membership dues include \$12 for ASN Kidney News subscription. Copyright© 2014 All rights reserved



Corporate Supporters

The ASN Corporate Support Program recognizes supporters year round for their generous contributions to the Society. Through this program, supporters help ASN lead the fight against kidney disease. ASN gratefully acknowledges the following companies for their contributions in 2014.

Diamond Level











Platinum Level



CORRECTION

The article, "20 Things to Know about Your ASN" in the October/November issue of *Kidney News* included incorrect numbers for ASN's membership. Item 19 in the article should have read: "Of ASN's 15,560 members, 5306 (34 percent) are from outside the United States."The article incorrectly stated: "Of ASN's 14,928 members, 6184 (41 percent) are from outside the United States."*Kidney News* apologizes for the error. The numbers are stated correctly in the online *KN*.

RRT Can Play a Critical Role in Treating Ebola Patients

By Eric Seaborg

Recent Ebola cases have shown that dialysis can play a key role in the survival of critically ill patients. Given the potential importance of renal replacement therapy (RRT) for these patients—and the need for biocontainment procedures to protect caregivers—nephrologists should take active roles in creating treatment plans at their facilities, experts said.

The recovery of a patient at Emory University Hospital shows that even patients at the point of organ failure can recover from Ebola virus disease if given aggressive supportive therapy, according to Harold A. Franch, MD, a nephrologist who helped treat this first Ebola patient known to have received RRT. Franch presented this case study at a special session at Kidney Week as well as in a recent article in the *Journal of the American Society of Nephrology*.

"Now we know that you can recover kidney function, so the damage is not irreversible," Franch said. Supportive therapy—especially fluid replacement—can buy the time needed for a patient's body to mount an immune response to overcome the viral attack, at least in some cases.

Ebola has several effects that can lead to acute kidney injury (AKI) and the need for RRT. These effects include massive fluid loss from vomiting and diarrhea leading to hypovolemia, a systemic inflammatory response syndrome, hemorrhagic fever and clotting abnormali-

ties that increase susceptibility to bleeding, and more, said Sarah Faubel, MD, professor of medicine at the University of Colorado, Denver, and head of ASN's AKI Advisory Group. Faubel also spoke at the Kidney Week special session. "The medical indications for renal replacement therapy in Ebola virus are similar to those in other patients with acute kidney injury, and involve considerations such as volume control, electrolyte balance, and the severity of kidney dysfunction," Faubel said. "In critically ill patients, nephrologists have great experience in considering the risks and benefits of RRT, and the medical decision to start it should follow the usual course."

The decision may follow standard considerations, but the implementation is different because of the need to isolate the patient. A unique aspect of Ebola treatment is that staff protection is as important as the patient outcome. "You will not succeed unless you have an isolation environment that protects your staff safety and the safety of the community," Franch said.

"The biggest lesson in terms of treatment of Ebola patients is that you have to play by the rules of the isolation unit," Franch told *Kidney News.* "When you are in an operating room, you have to do everything according to operating room standards to protect the patient. When you are in an isolation room, you have to do everything according to isolation procedures to protect the staff from infection."

A hospital should develop its plan for dealing with an Ebola patient well before any patient arrives. These plans should follow Centers for Disease Control and Prevention (CDC) guidelines and local community health department recommendations, Faubel said. "Given the potential need for dialysis and the complexity of performing dialysis in patients with Ebola virus disease (EVD), nephrologist involvement is essential in the planning phases of hospitals intending to care for patients with EVD," a guidance document developed by ASN recommends. The plan should address questions such as the use of anticoagulation, an approach for laboratory testing, and how to handle dialysis effluent and the other medical wastes. (Many of these treatment resources can be found online—see sidebar.)

For effective planning, nephrologists need a realistic

idea of the infectivity of the virus. Ebola virus is spread through direct contact with blood from infected patients, but can also spread via contact with other fluids such as urine, sweat, vomit, and diarrhea.

Franch said that Ebola is more like hepatitis B than HIV: "It can survive on surfaces about as long as hepatitis B, which isn't that long, but is long enough. It is not like HIV, which dies pretty much as soon as it gets on a surface. Ebola is a lipid-coated virus, so once you really dry it out, it dies. In a dialysis unit, you have to isolate hepatitis B patients, but you don't have to isolate HIV patients."

One factor that makes Ebola so infectious is its very high levels—in the billions of viruses per milliliter of blood—and it can also be present on the patient's skin. It is not transmitted through the respiratory route like influenza, but aerosolized bodily fluids are infectious. These characteristics call for extra caution in dialysis set-up, and argue for the use of continuous RRT to minimize blood spill possibilities.

The case of Thomas Eric Duncan in Dallas, in which two nurses treating him became infected, led the CDC to tighten its guidelines to recommend that personal protective equipment have full body coverage for all workers caring for Ebola patients.

The Emory team adopted procedures designed to minimize the possibility of healthcare worker exposure.

"We dedicated a pressure-controlled room, used point-of-care laboratory testing, [and used] dedicated ultrasound and x-ray machines that never left the room. Blood cultures were performed in the room and consulting physicians did not enter the room unless absolutely required," Franch said.

Much of the care relied on ICU nurses with specialized training in isolation protocols and in continuous RRT who volunteered for the duty, but some on-the-spot training was unavoidable. They followed isolation procedures such as checking the integrity of the protective gear

of those entering and exiting the isolation unit. The team used a single dialysis machine "with a small footprint that could stay in the room and had the flexibility to perform both continuous and intermittent modes of dialysis," Franch said, and anything that went into the isolation unit stayed there.

In keeping with Kidney Disease Improving Global Outcomes AKI guidelines, the team put the cannula in the right internal jugular, which is their local practice. Line placement is considered a center-specific consideration, and hospitals should stick with practices they have experience with. This is no time to experiment with new procedures, Faubel said.

Franch said that to minimize filter changes in the dialysis unit, the patient received anticoagulation therapy, which has its own problems because Ebola is a hemorrhagic disease. "For this reason, we used regional citrate anticoagulation with peripheral calcium replacement and regular ionized calcium measurements. While this approach worked extremely well, alkalosis from metabolism of the citrate does become a problem," Franch said.

Emory University Hospital successfully treated a pair of other patients whose kidney function remained normal despite arriving from Africa on day 10 and day 14 of their illnesses. The RRT patient was admitted much earlier, on day 4 of his disease, and developed AKI despite the aggressive supportive therapy. Some observers have doubted whether continued treatment could work when the disease has progressed this far. But with RRT and other support, the patient's immune system responded. "The biggest lesson is that someone can recover from this," Franch concluded.

Resources for Ebola Preparation and Treatment

As the Ebola epidemic reached beyond Africa with patients in the United States and Europe, ASN responded quickly with a wealth of resources, from a podcast on Ebola and dialysis to a well-attended special session at Kidney Week.

The Centers for Disease Control and Prevention and other healthcare leaders reacted as well, and ASN has gathered links to every topic related to nephrology at the page: http://www. asn-online.org/news/2014/1017-ebola.aspx

Some of the most important links on the page are to:

- ASN Frequently Asked Questions Regarding Ebola Virus Disease and Dialysis.
- CDC Recommendations for Safely Performing Acute Hemodialysis in Patients with Ebola Virus Disease in U.S. Hospitals
- A podcast featuring Harold Franch, MD, who successfully dialyzed a patient with Ebola, and Sarah Faubel, MD, chair of ASN's Acute Kidney Injury Advisory Group, discussing Ebola's effects on kidney function and considerations nephrologists should take into account when treating a patient with Ebola.

The page also includes links to a CDC fact sheet on personal protective equipment for Ebola, a CDC hospital checklist for Ebola preparedness, CDC Ebola resources, and the World Health Organization Ebola portal.

Emory University, where a patient was successfully treated using dialysis, has a webpage with "Emory Healthcare Ebola Preparedness Protocols": http://www.emoryhealthcare.org/ebola-protocol/ehc-message.html

Details on the treatment of this patient along with proposed clinical practice guidelines can be found in "Successful Delivery of RRT in Ebola Virus Disease," epublished in *Journal of the American Society of Nephrology*: http:// jasn.asnjournals.org/content/early/2014/11/13/ASN.2014111057. abstract

Another recent article about two other Emory patients, "Clinical Care of Two Patients with Ebola Virus Disease in the United States," was published in the *New England Journal of Medicine* and can be found at: http://www.nejm.org/ doi/full/10.1056/NEJMoa1409838

High-Impact Clinical Trials Offer New Insights into ADPKD and AKI

By Tracy Hampton with Kurtis Pivert

total of 27 late-breaking clinical trials were presented at ASN Kidney Week 2014 in Philadelphia. These studies detailed new understandings and innovations in multiple therapeutic areas, including acute kidney injury (AKI), autosomal dominant polycystic kidney disease (ADPKD), dialysis, and diabetic nephropathy. This article highlights some of the leading science presented at the oral plenary High-Impact Clinical Trials session that potentially could influence the clinical approach of kidney health professionals in the United States and beyond.

HALT PKD trials

Two new prospective, multicenter randomized clinical trials sought to understand the influence of blood pressure control on disease progression and comorbidities in patients with ADPKD, the fourth leading cause of end stage renal disease (ESRD). A combination of two studies, the HALT PKD trials first evaluated the effects of rigorous blood pressure control on disease progression and whether combined antihypertensive therapies conferred an additional benefit.

The HALT A study enrolled 558 patients with early ADPKD to determine if rigorous blood pressure control conferred benefits over standard blood pressure control related to a reduced rate of increase in total kidney volume and greater declines in measures of heart and kidney problems (1). Healthy patients between 15 and 49 years old (with an eGFR greater than 60 mL/min/1.73 m²) were randomized to either standard blood pressure control (120–130/70–80 mm Hg) or low blood pressure control (95–110/60– 75 mm Hg) groups. The primary end point was disease progression measured as percent change in total kidney volume.

Low blood pressure control was well tolerated and resulted in a 14.2 percent slower growth of total kidney volume over five years, while conferring some cardiovascular benefits. "Hypertension was very well controlled in both treatment groups," said lead author Arlene Chapman, MD. "The results emphasize the potential importance of early detection and aggressive treatment of hypertension in ADPKD."

In the HALT B study, researchers included 486 ADPKD patients with chronic kidney disease (CKD) stage 3 to find out if treatment with an angiotensinconverting enzyme (ACE) inhibitor was safe and by itself sufficient to achieve blood pressure control in the majority of patients (2). This time, patients were randomized to either ACE inhibitor monotherapy or ACE inhibitor plus an angiotensin-receptor blocker (ARB).

Although both treatment regimens were well tolerated, dual therapy didn't confer any additional treatment benefit. "Both studies showed that ACE inhibitors alone or in combination with ARBs are safe and well tolerated and achieve excellent blood pressure control in the majority of patients with AD-PKD," said lead author Vincente Torres, MD, PhD. "However, both failed to demonstrate any superiority of dual blockade with an ACE-I and an ARB compared to an ACE inhibitor alone." Hypertension in ADPKD develops early and associates with disease progression.

Glucose control could help reduce diabetic nephropathy incidence

Longitudinal data obtained in a post-trial observational study suggest that glucose control may be a key determinant for ESRD risk. The ADVANCE-ON Trial found patients who maintained strict glucose control demonstrated evidence of a sustained and significant reduction in ESRD over a long period of time with a median of nearly 10 years.

Follow-up of 8494 patients in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (AD-VANCE) trial, which is the largest clinical trial on diabetes, revealed that intensive glucose control leads to long-term reductions in the risk of developing ESRD (3).

"Our study also suggests that the benefits are greater when treatment is begun early in the course of the disease, and in people in whom blood pressure is wellcontrolled," said lead author Vlado Perkovic, MBBS, PhD, FASN. "These results suggest that finding better ways to control glucose levels is key to preventing the epidemic of kidney failure due to type 2 diabetes around the world."

New understandings in AKI

Two studies evaluated potential therapies for AKI in the hospital setting, a common complication that can lead to kidney failure and in some cases death.

The first examined the use of aspirin and clonidine with non-cardiac surgery to determine if it could reduce the incidence of AKI. "We need treatments to prevent AKI in the surgical setting, and early data suggested taking aspirin in this regard might be beneficial," said Amit Garg, MD, the study's author. The substudy of the PeriOperative ISchemic Evaluation-2 (POISE-2) Trial included 6905 patients undergoing non-cardiac surgery. Investigators found that use of aspirin around the time of surgery increased the risk of major bleeding, which was associated with a greater risk of subsequent AKI. The use of clonidine (a medication used to treat hypertension) around the time of surgery increased the risk of low blood pressure, which was associated with a greater risk of subsequent AKI.

Compared with placebo, neither aspirin nor clonidine altered the risk of most AKI observed after major non-cardiac surgery. "Approximately 200 million adults undergo major non-cardiac surgery each year, and among patients taking aspirin prior to surgery there is substantial practice variability as to whether it is held or not in the perioperative period," the study investigators noted (4).

Another AKI study evaluated the use of mesenchymal stem cells in patients undergoing cardiac bypass surgery. The ACT-AKI study built on previous work that demonstrated the cells' potential to prevent AKI and promote recovery of renal function after it occurred. A trial of 156 patients who developed AKI following cardiac surgery found that treatment with certain stem cells did not shorten the time it took patients to achieve complete kidney recovery, nor did it decrease their risk of dying prematurely or needing dialysis. Unfortunately, "AKI is a common condition and there is no effective treatment," the researchers said (5).

Advances in dialysis reported

Several studies reported research on innovations in care for patients on dialysis. The first study examined a new approach to in-stent restenosis, a common problem in this population. It included 265 dialysis patients, and found that the Fluency® Plus Endovascular Stent Graft-which is placed inside a blocked stent to re-open it and allow adequate blood to flow and dialysis to take place-was superior to balloon angioplasty alone through 6 months. The Fluency® Plus Endovascular Stent Graft was better for restoring blood flow and keeping the area open longer. "Instent restenosis is a common problem in the care of ESRD patients. This study represents the first level-1 evidence for the use of stent-grafts in the treatment of both arteriovenous fistula and arteriovenous graft stenosis," said lead author Alexander Yevzlin, MD (6).

Another, ACTIVE Dialysis Multinational Trial, examined the use of extended hemodialysis hours to determine if it would improve patient outcomes. Among 200 patients on dialysis, extending weekly dialysis hours for 12 months did not improve quality of life, but was linked with improvements in some laboratory measures (such as potassium and phosphate blood levels) and a reduced need for blood pressure medications (7).

Disclosure information is available at

http://www.asn-online.org/education/kidneyweek/2014/program-faculty.aspx. Funding information is available in the Kidney Week 2014 Abstract Supplement at http://www.asn-online.org/abstracts.

References

- Chapman AB, et al. HALT Progression of Polycystic Kidney Disease (HALT PKD) Trials: Primary Results of a 2x2 Factorial Trial in Early Stage CKD. J Am Soc Nephrol 25 (Suppl); 2014:B1.
- Torres VE, et al. HALT Progression of Polycystic Kidney Disease Trials: Primary Results of a Randomized Trial in Moderately Advanced Stage CKD. *J Am Soc Nephrol* 25 (Suppl); 2014:B1.
- Perkovic V, et al. ADVANCE-ON: Long Term Benefits Of Intensive Glucose Control For End-Stage Kidney Disease. *J Am Soc Nephrol* 25 (Suppl); 2014:B1.
- Garg AX. Effect of Perioperative Aspirin and Clonidine on Acute Kidney Injury. J Am Soc Nephrol 25 (Suppl); 2014:B2.
- Swaminathan M, et al. ACT-AKI: A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of AC607 for the Treatment of Acute Kidney Injury in Cardiac Surgery Subjects. *J Am Soc Nephrol* 25 (Suppl); 2014:B3.
- Yevzlin AS, et al. Six-Month Results of the RES-CUE Trial: Fluency[®] Plus Endovascular Stent Graft versus PTA for In-stent Restenosis. *J Am Soc Nephrol* 25 (Suppl); 2014:B2.
- 7. Impact of Extended Weekly Hemodialysis Hours on Quality of Life and Clinical Outcomes: the ACTIVE Dialysis Multinational Trial. *J Am Soc Nephrol* 25 (Suppl); 2014:B2.



At Amgen, we pour commitment, passion, and a drive for perfection into every biologic medicine we make.

From innovative biotechnology to extensive experience in biologic manufacturing, see how Amgen strives to deliver on its commitment to your patients.





©2014 Amgen Inc. All rights reserved. 80012-R2-V1

Take a deeper look at our reliability and quality visit biotechnologybyamgen.com Download the LAYAR app on your smartphone and scan this page.

Exercise May Slow Kidney Disease Progression

Patients with stage 3 to 4 chronic kidney disease (CKD) assigned to an exercise/rehabilitation intervention have better maintenance of kidney function at one-year follow-up, according to preliminary research presented at Kidney Week 2014.



In a pilot study, consultant renal physiotherapist Sharlene A. Greenwood of King's College London and colleagues evaluated an exercise training program for patients with predialysis CKD. Ten patients received the study intervention, which consisted of thrice-weekly exercise sessions at a gym setting in a community hospital. Another 10 patients received usual care. The exercise programs were individualized, accounting for patient choice and aiming for a combination of aerobic and resistance exercises. Aerobic exercise was predominantly performed on recumbent stationary exercise cycles, at an intensity corresponding to 80 percent heart rate reserve with maximum heart rate, based on incremental exercise testing. Resistance training was prescribed at 80 percent of one repetition maximum. The intervention also included an individual session with a senior renal physiotherapist for discussion of exercise and personal goals with use of a motivational interviewing approach.

Kidney function was assessed by comparing the rate of change in serum creatinine-based estimated GFR (eGFR) for each participant for 12 months before the study versus during the 12-month intervention period. Other outcomes of interest included pulse wave velocity, exercise capacity (VO₂ peak), waist circumference, and body weight. Eight patients in the intervention group and 10 control individuals completed the study.

At the end of 12 months, patients assigned to the exercise/rehabilitation group had better-preserved kidney function. The mean difference in eGFR was 7.8 mL/min/1.73 m²/year, compared with the usual care group.

Exercise/rehabilitation was also associated with reduced body weight and improved exercise capacity. After adjustment for baseline differences, patients in the intervention group had a 5.6 kg reduction in body weight and a 7.1 cm reduction in waist circumference, with a 5.7 mL/kg/min increase in relative VO₂ peak.

There was also a significant 2.30 m/second reduction in pulse wave velocity in the intervention group. The eGFR benefit was inversely correlated with the changes in pulse wave velocity and waist circumference.

Patients with stage 3 to 4 CKD have reduced exercise capacity, which may contribute to their risk of cardiovascular disease—the leading cause of death in CKD. Exercise training has the potential to preserve kidney function and improve cardiovascular risk factors in predialysis patients with CKD.

This pilot study suggests substantial benefits of an exercise/rehabilitation program for patients with stage 3 to 4 CKD. The benefits include a slower decline in kidney function after 12 months of exercise training, compared with usual care.

Together with improvements in exercise capacity and body weight, the exercise/rehabilitation program may be associated with improved quality of life in this group of patients. "Although small, our study suggests that long-term tailored exercise prescription with motivational interviewing is a feasible approach for exercising patients with progressive CKD, and sets the scene for a large multicenter study," Greenwood said.

New Findings on Diet and Kidney Disease

Research presented at Kidney Week 2014 highlights dietary factors affecting kidney disease outcomes including a study reporting that a "healthy diet" and lower sodium intake are associated with a reduced risk of major renal outcomes. Another report draws attention to the potentially high levels of potassium added to some "reduced-sodium" foods.

Nephrologist Andrew Smyth, MB, of National University of Ireland Galway and his colleagues presented the results from the Diet and Health Study of the National Institutes of Health and the American Association of Retired Persons. On the basis of findings on food frequency questionnaires completed by nearly 545,000 participants, the researchers evaluated the relationship between diet quality, sodium and potassium intake, and major renal outcomes—dialysis or death from renal causes. The study evaluated several different definitions of a "healthy diet": the Healthy Eating Index, the Alternate Healthy Eating Index, the Mediterranean Diet Score, and the Recommended Food Score, along with sodium and potassium intake.

On three of four diet quality measures, a healthy diet was associated with a lower risk of dialysis or death from a renal cause; there was no association with the Recommended Food Score. On multivariate analysis, the risk of the combined outcome was 16 to 23 percent lower for participants in the highest quintile of dietary quality, compared with the lowest quintile.

Said Smyth: "We found that high sodium intake, average 4.7 g/day, was associated with an increased risk, but no difference between low and moderate intakes: average 2.0 and 3.1 g/day." High potassium intake was associated with a reduced risk. The risk was 19 percent higher for participants in the highest quintile of sodium/potassium ratio. The researchers conclude, "Our findings extend the known benefits of healthy eating and show that the consumption of a healthy diet, including reducing sodium intake from high levels and increasing potassium intake, may protect from future major renal endpoints."

Arti Sharma Parpia, RD, of St. Michael's Hospital, Toronto, and colleagues from the University of Toronto evaluated the protein, sodium, phosphorus, and potassium content of "reduced-sodium" meat and poultry products sold at grocery stores. "Food manufacturers may use phosphate and potassium additives to replace the functional and flavor properties of sodium, and the amount is usually not listed on food labels," the researchers write.

They found that sodium-reduced products contained

25 to 55 percent less sodium than their non-sodium-reduced counterparts: the mean difference was 460 mg per 100 g. The sodium-reduced products also contained on average 47 percent more potassium, with a wide variability in potassium content: from 210 to 1500 mg per 100 g. Potassium-containing additives were found on the ingredients list of 63 percent of sodium-reduced products, compared with 25 percent of non-sodium-reduced products.

Phosphorus and protein levels did not differ for the two groups of products. "Potassium additives are frequently added to sodium-reduced meat and poultry products in amounts that significantly contribute to the potassium load for CKD patients," the researchers conclude. "Patients requiring a potassium restriction should limit their intake of sodium-reduced meat and poultry products."



Poor Air Quality Linked to CKD Risk

ould differences in air quality contribute to the observed regional variations in chronic kidney disease (CKD)? A study presented at Kidney Week 2014 finds a higher prevalence of recognized CKD in counties of the United States with higher particulate air pollution.

Epidemiologist Jennifer L. Bragg-Gresham, PhD, of the University of Michigan and colleagues evaluated differences in pollutant levels—specifically, fine particles smaller than 2.5 μ m (PM_{2.5})—as potentially contributing to regional differences in CKD prevalence.

On the basis of Medicare claims data from 1.1 million persons aged 65 years and older, the prevalence of CKD by county ranged from zero to 60 percent, with a median of 16 percent. Associations between levels of $PM_{2.5}$, determined from U.S. Environmental Protection Agency air-quality data made publicly available through the WONDER online database of the Centers for Disease Control and Prevention, and prevalence of recognized CKD in the Medicare data were analyzed.

"We found that poorer air quality was associated with a higher prevalence of CKD," Bragg-Gresham and coauthors write. With $PM_{2.5}$ treated as a continuous variable, each increment of 4 µg/m³ in $PM_{2.5}$ was associated with a 3 percent higher CKD prevalence, after adjustment for individual-level confounders.

When counties were grouped by quartiles of $PM_{2.5}$, a threshold at approximately 14 µg/m³ was observed for higher CKD prevalence. This is much lower than the level typically considered unhealthy (40 µg/m³) for sensitive groups, such as children, the elderly, and people with cardiorespiratory disease.

Well recognized individual risk factors, such as age, diabetes, and hypertension explain some, but not all, of the wide regional variation in CKD prevalence. As yet unrecognized environmental factors, such as air pollution, might account for some part of the additional variability.

Although observational studies cannot show causal relationships, this large cross-sectional study suggests that higher $PM_{2.5}$ levels in a county are associated with higher rates of diagnosed CKD. The researchers call for further studies to clarify this relationship, including laboratory diagnosis of CKD, longitudinal designs, assessment of other air and environmental pollutants, and measures of individual pollutant exposure.

"If this association is borne out by future studies, it would have implications for reducing air pollution



exposure for those with CKD and also for those at risk for the condition," Bragg-Gresham said. "The potential public health significance of this finding is even greater for regions and countries with much higher levels of air pollution than the United States."

Industry Spotlight

DaVita Activates Compliance after \$400 Million Settlement

DaVita announced in May 2013 that it had set aside \$300 million in case the company would be required to pay a federal fine, revealed CEO Kent Thiry, during what he termed a "sober" conference call to announce quarterly results. Eventually, the company had set aside a total of \$414 million, so it would be prepared to pay for a potential violation of the False Claims Act when the time came.

The settlement money has finally come due, and amounted to \$387 million plus interest accrued between February and October of this year.

In late October, the U.S. Department of Justice (DoJ) announced that DaVita had agreed to pay \$350 million to resolve claims that the company had violated the False Claims Act. The claims included paying kickbacks to induce the referral of patients to DaVita dialysis clinics. Headquartered in Denver, DaVita has dialysis clinics in 46 states and the District of Columbia.

A fine of \$39 million was also part of the settlement to the federal government, payment for two particular deals. In addition, another \$11.5 million has to be paid to cover Medicaid (state) compensation. Interest charges on the settlement amount began in Feb. 2014 at the rate of 2.25 percent per year, the DoJ announced.

For its part, DaVita announced that the investigation, which covered a period from March 2005 to February 2014, was resolved with findings that "patient care was never at issue, nor were billing or payment practices." The DaVita statement added: "We are proud of our commitment to compliance over our 15-year history. We have worked incredibly hard to get things right and it is our belief there was no intentional wrongdoing."

The DoJ statement noted that DaVita had joint ventures with and eventually acquired Gambro in 2005. Gambro was accused of fraud, had to pay more than \$300 million in a settlement, and had to unwind its own joint venture agreements as part of that settlement. DaVita had

compliance agreements in place related to its Gambro relationship and eventual ownership.

In the current settlement, DaVita said it would "undo 11 joint venture transactions covering 26 of our 2,119 clinics." According to the *Denver Business Journal*, the U.S. Attorney's Office also announced that, "in conjunction with today's announcement," it was closing a criminal probe into two joint ventures involving DaVita and doctors. The \$39 million civil forfeiture agreed to by DaVita was "based upon conduct related to two specific joint venture transactions entered into in Denver," the office said, implying that ownership although crimes were not discovered in relation to the two joint ventures. (Forfeiture describes the process wherein a civil court, after all the interested parties have had a chance to make their case, orders a change in ownership of the property, without criminal charges.)

DaVita also will institute a strictly outlined compliance program through a Corporate Integrity Agreement that includes many required elements and potential fines if compliance requirements fail to be established, such as: "unwinding of the Subject Joint Venture Clinics, except to the extent covered by a Monitor's certification." The program calls for an independent monitor, a written code of conduct, detailed training of DaVita staff and others covered under the settlement, including board members; and hiring a chief compliance officer.

Now DaVita will have to start entering into transactions that uncouple 11 of the same clinics that it worked to partner with. The settlement noted that for 9 years, until February 2014, DaVita had identified physicians or physician groups with patient populations suffering from renal disease. DaVita, the claim said, "offered them (the physicians) lucrative opportunities to partner with DaVita by acquiring or selling an interest in the dialysis clinics to which their patients would be referred," and the physicians also could not compete with the DaVita clinics nor refer patients to other dialysis providers.

Something ? to Say ?

ASN Kidney News accepts correspondence in response to published articles. Please submit all correspondence to kidneynews@asn-online.org

Policy Update

CMS Final Rule for 2015 Holds No Surprises

By Mark Lukaszewski

n Friday, October 31, 2014, the Centers for Medicare & Medicaid Services (CMS) released its 2015 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Quality Incentive Program (QIP) final rule for calendar years 2017 and 2018. This article provides a basic overview of the key takeaways of the rule.

After close inspection, ASN has concluded that the final rule did not contain any unexpected adjustments to the ESRD PPS or QIP and does not differ substantially from the proposed rule. The society determined it is likely that the 2015 rulemaking cycle will have a more pronounced effect on the program, as CMS is expected to provide further clarity on how new drugs may be added to the bundle, as well as make changes to the low-volume adjuster.

ESRD PPS

CMS finalized every aspect of the Protecting Access to Medicare Act (PAMA) pertaining to the ESRD PPS, including setting the base rate at a 0.1 percent increase from 2014 and delaying the inclusion of oral-only drugs until 2024. CMS noted that it believes the agency has the authority to add new services to the bundle, an issue that has recently been debated within the kidney community.

CMS addressed the provision of dialysis beyond the standard three times per week, restating its position that facilities must furnish medical justification for more frequent dialysis, and that dialysis modality choice does not constitute medical justification. The agency also stated that while it is not changing its policy regarding payment for drugs that are included in the PPS but are furnished for the treatment of ESRD, it recognizes that there is ongoing concern regarding patient access to prescription medications. CMS is considering various alternatives for dealing with this issue and plans to put out guidance in the near future.

Quality Improvement Program

In terms of the QIP, CMS finalized a proposal to implement a risk-standardized 30-day all-cause hospital readmissions (SRR) measure. ASN strongly supported this measure in concept but recommended against finalizing the measure owing to numerous concerns with the measure and methodology as designed. Notably, the National Quality Forum voted against the SRR measure when it was considered for endorsement this fall.

On a more positive note, CMS decided against adding a new measure to assess conditions treated by oral-only drugs, which is consistent with ASN's encouragement to utilize a few highly meaningful measures rather than adding more watered-down measures. In addition, CMS finalized its proposal to remove the "Hgb >12 g/dL anemia management measure," a change ASN has supported for several years because the measure is topped out.

ASN, together with the greater kidney community, will continue to work together with CMS in order to make sure that the measures being developed guarantee the highest quality care possible for the millions of Americans with kidney disease. To learn more about this issue, or to read the ASN comment letter to CMS, please visit the ASN advocacy page at http://www.asn-online.org/policy/.

Final Physician Fee Rule Includes Wins for Kidney Community

By Mark Lukaszewski

n Halloween Eve 2014, CMS released the 2015 Physician Fee Schedule final rule, finalizing several important victories for ASN and other advocates in the kidney community.

A top ASN priority, also supported by other stakeholders, was to modify the billing rules to allow nephrologists to bill the full month of care when a home dialysis patient has been hospitalized during that month. CMS finalized the proposal it laid out in the proposed rule that would allow nephrologists who complete monthly assessment of home dialysis patients and at least one face-to-face patient visit to bill for the full monthly MCP code for home dialysis patients who are hospitalized that month. Previously, nephrologists had to bill the per diem code in months when their home dialysis patients were hospitalized. ASN and other advocates, including the Home Dialysis Alliance and Kidney Care Partners, supported this change,.

Also in the final rule, CMS addressed concerns raised by ASN and others in the Continuing Medical Education (CME) community that physicians attending certified CMS programs like ASN Kidney Week could get unfairly reported in the Open Payments program. The Open Payments program is an online federal initiative to increase transparency regarding physicians' financial relationships with industry, such as gifts and travel.

CMS established reporting rules that *specifically exclude* CME payments from the Open Payments program, including speaker-related payments and tuition support for attendees, so long as they are not directed by a commercial supporter. Although CMS does not yet have the legal authority from Congress to designate patients' homes as qualifying telehealth sites, ASN has and will continue to encourage both CMS and Congress to consider the potential benefits of adding the monthly capitation payment (MCP) services for home dialysis patients to the Medicare telehealth list as federal statute regarding telehealth sites evolves. This could enable more patients to consider dialysis at home, and reduce the travel burden for both patients and providers. CMS did note that it could pilot telehealth MCP care through its Innovation Center, opening up a new advocacy angle for 2015.

For more information on the final rule, please visit ASN's policy webpage at http://www.asn-online.org/policy/

Journal View

Dabigatran Linked to Excess Bleeding Risk

The risk of bleeding complications is increased for patients with atrial fibrillation taking dabigatran compared with warfarin—and patients with chronic kidney disease are among the highest-risk subgroups, according to a report in *JAMA Internal Medicine*.

The retrospective cohort study used pharmacy and medical claims data for a random 5 percent sample of Medicare beneficiaries in 2010 to 2011. Two groups of patients who started anticoagulant treatment within 60 days after diagnosis of atrial fibrillation were identified: 1302 receiving dabigatran and 8102 receiving warfarin. Episodes of major and minor bleeding by site were compared between groups, with propensity score weighting to account for differences in patient characteristics.

Patients starting treatment with dabigatran had higher bleeding rates than did those starting warfarin: hazard ratio (HR) 1.30 for any bleeding event and 1.58 for major bleeding. The adjusted rates of major bleeding were 9.0 percent with dabigatran versus 5.9 percent with warfarin. The risk of gastrointestinal bleeding was also higher with dabigatran: HR 1.85.

The rates of most types of bleeding complications were higher with dabi-

gatran, including hematuria (HR 1.41), vaginal bleeding (HR 2.27), hemarthrosis (HR 2.78), and hemoptysis (HR 1.49). The exception was intracranial hemorrhage: HR 0.32 with dabigatran.

The excess bleeding risk remained significant in defined high-risk subgroups. The rates of major bleeding with dabigatran were particularly high for African American patients (HR 2.12) and for patients with chronic kidney disease (HR 2.07).

Soon after the approval of dabigatran, there were reports of severe bleeding events, particularly among elderly patients and those with renal impairment. Subsequent studies of this risk have yielded conflicting results.

This large analysis of Medicare beneficiaries with atrial fibrillation supports concerns about higher bleeding risk with dabigatran, compared with warfarin. The authors urge caution in prescribing dabigatran, especially to African Americans and patients with chronic kidney disease renal impairment. They also highlight the elevated risk of gastrointestinal bleeding across all patient subgroups [Hernandez I, et al. Risk of bleeding with dabigatran in atrial fibrillation. *JAMA Intern Med* doi:10.1001/jamainternmed.2014.53980].



The American Society of Nephrology thanks the following members for their dedication and service to the society concluding in 2014

Emaad M. Abdel-Rahman, MD, PhD, FASN Christine K. Abrass, MD Anupam Agarwal, MD, FASN Charles E. Alpers, MD Sharon P. Andreoli, MD Mohammed Javeed Ansari, MD Ralph C. Atkinson III, MD James L. Bailey, MD Carlton M. Bates, MD L. Ebony Boulware, MD Gregory Lee Braden, MD Matthew D. Breyer, MD, FASN Wendy Weinstock Brown, MD Teri Browne, PhD John M. Burkart, MD Laura Byham-Gray, PhD Thomas J. Carroll, PhD Kerri L. Cavanaugh, MD Kerry C. Cho, MD Michel Chonchol, MD Mark E. Cooper, MBBS, FASN Dinna N. Cruz, MD Stephen F. Darrow, MD Ira D. Davis, MD Tejas P. Desai, MD Prasad Devarajan, MD Zheng Dong, PhD, FASN Jeremy S. Duffield, MD, PhD Allison A. Eddy, MD, FASN Fredric O. Finkelstein, MD Michael F. Flessner, MD, PhD Carlos D. Flombaum, MD Joseph T. Flynn, MD, FASN Agnes B. Fogo, MD Susan L. Furth, MD David Goldsmith, MD, FASN Stuart Goldstein, MD R. Ariel Gomez, MD Debra J. Hain, PhD, APRN Peter C. Harris, PhD

Catherine K. Hathaway, MD Brenda Hemmelgarn, MD, PhD Melanie P. Hoenig, MD Lawrence B. Holzman, MD Thomas H. Hostetter, MD Joanna Hudson, PharmD, FASN Benjamin D. Humphreys, MD, PhD, FASN T. Alp Ikizler, MD, FASN Melanie S. Joy, PharmD, PhD, FASN George A. Kaysen, MD, PhD, FASN Donald E. Kohan, MD, PhD, FASN Abhijit V. Kshirsagar, MD Pascale H. Lane, MD, FASN Kevin M. Lee, MD Alan B. Leichtman, MD Edgar V. Lerma, MD, FASN Andrew S. Levey, MD Moshe Levi, MD, FASN Christoph Licht, MD, FASN Ruisheng Liu, MD, PhD Xun-Rong Luo, MD, PhD Glen S. Markowitz, MD Teri J. Mauch, MD, FASN Alicia A. McDonough, PhD Bruce A. Molitoris, MD, FASN Patrick H. Nachman, MD, FASN N. Stanley Nahman, Jr., MD Suzanne M. Norby, MD, FASN Victoria F. Norwood, MD Amy Barton Pai, PharmD, FASN Dipen S. Parikh, MD Samir M. Parikh, MD Uptal D. Patel, MD Martha Pavlakis, MD Didier Portilla, MD Caroline Jennette Poulton, MSW Neil R. Powe, MD, FASN Susan E. Quaggin, MD Jai Radhakrishnan, MD, FASN Maria Pia Rastaldi, MD, PhD

Andrew J. Rees, MBChB Rudolph A. Rodriguez, MD Mark E. Rosenberg, MD, FASN Mitchell H. Rosner, MD, FASN Brad H. Rovin, MD, FASN David J. Salant, MD Jeff M. Sands, MD, FASN Jeffrey R. Schelling, MD Detlef O. Schlondorff, MD Joseph I. Shapiro, MD, FASN Andrey S. Shaw, MD Michael J. Somers, MD Stefan Somlo, MD Matthew A. Sparks, MD, FASN Titte R. Srinivas, MD Wendy L. St. Peter, PharmD, FASN Ana R. Stankovic, MD, FASN Manikkam Suthanthiran, MD, FASN Timothy A. Sutton, MD, PhD, FASN Jens Titze, MD Raymond R. Townsend, MD Leonidas Tsiokas, PhD J. Kevin Tucker. MD Delphine S. Tuot, MD Robert J. Unwin, MD, PhD Sushrut S. Waikar, MD Karen M. Warburton, MD Janet L. Welch, PhD Paul A. Welling, MD Roger C. Wiggins, MD Alexander C. Wiseman, MD Jack Work, MD

Policy Update

ASN Goes to NIH and PCORI

By Grant Olan

n September 19, 2014, ASN Secretary-Treasurer and Research Advocacy Committee Chair John R. Sedor, MD, FASN, joined other members of the committee and several of the society's advisory groups to visit the National Institutes of Health (NIH) and Patient-Centered Outcomes Research Institute (PCORI) for "Kidney Research Advocacy Day."

ASN began annual visits to NIH in 2012 to raise the profile of kidney disease, promote more kidney-related research, and encourage more cross-institute collaboration. This year, Kidney Research Advocacy Day participants met with leaders of the National Heart Lung and Blood Institute (NHLBI), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and National Institute on Aging (NIA). The NIAMS and PCORI meetings were the first one-on-one meetings ASN has had with their leaders.

An internal ASN study of kidney research revealed that less than 1 percent of what the federal government spends on the cost of care for patients with kidney disease is invested in kidney research (approximately \$80 billion in Medicare expenditures vs. \$650 million for kidney research). The cost of just the Medicare End Stage Renal Disease (ESRD) program is nearly \$35 billion, which is more than the entire budget for NIH (less than \$30 billion in 2014).

Moreover, in 2013 NIH spent less per patient on kidney research vs. heart disease, cancer, and HIV/AIDS (\$30 on kidney research per patient compared to \$61, \$534, and \$2,898, respectively).

U.S. Congressional Kidney Caucus Co-Chair Rep. Tom Marino (R-PA) recently requested a review of federal investments in kidney research from the Government Accountability Office (GAO), a bipartisan agency that is highly regarded by Congress. Obtaining a congressional request for a GAO report on this topic is the cornerstone of ASN's aggressive new Research Advocacy Strategic Plan to bolster support for more federal kidney research funding.

"I believe the GAO report is a crucial first step in understanding the current kidney research landscape, and anticipate it will confirm that kidney research is underfunded," Dr. Sedor said.

"I believe the report will pay dividends for research funding down the line," ASN President Jonathan Himmelfarb, MD, FASN added. "Once complete, ASN looks forward to sharing the results with the entire kidney community."

PCORI and each of the NIH institutes were receptive to ASN's concerns and expressed interest in working with the society to advance kidney-related research. Below are some takeaways from the Kidney Research Advocacy Day meetings.

National Heart Lung and Blood Institute (NHLBI)

ASN met with Lawrence J. Fine, MD, Branch Chief, Clinical Applications and Prevention Branch, NHLBI, and other senior staff at the institute. NHLBI supports collaboration with NIDDK and kidney-related initiatives, such as an Ischemia-Chronic Kidney Disease ancillary study. Most heart trials exclude patients with advanced kidney disease despite the fact that heart disease is the leading cause of death for that population. ASN encouraged the institute to also measure albuminuria as well as collect and archive urine samples (for use by the research community) in the study and as many other studies as possible.

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

ASN met with NIAMS Deputy Director Robert H. Carter, MD, and other

senior staff. NIAMS supports lupus nephritis research. A new NIH initiative called Accelerating Medicines Partnership (AMP) will explore possible biological pathways for treating lupus nephritis. AMP is a public-private partnership between NIH, industry, and nonprofit groups to increase the number of new diagnostics and therapies for patients and reduce the time and cost of developing them.

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

ASN met with NIBIB Acting Deputy Director William J. Heetderks, MD, PhD, and other senior staff. NI-BIB supports an initiative called the Quantum Grants Program. The goal is to make a "profound (quantum) impact on the prevention, diagnosis, or treatment of a major disease or national public health problem through the development and implementation of biomedical technologies within 10 years." The program is funding a project to develop an implantable bioartificial kidney.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

ASN met with NIDDK Director Griffin P. Rodgers, MD, Deputy Director Gregory G. Germino, MD, Kidney Urologic and Hematologic Diseases Division Director Robert A. Star, MD, and other senior staff. In addition to the issues outlined above, ASN and NIDDK discussed expanding NIH's loan repayment to include adult bench research, a possible 2015 NIDDK health disparities initiative and other institute research funding priorities, and the Kidney Research National Dialogue.

National Institute on Aging (NIA)

ASN met with NIA Deputy Director Marie A. Bernard, MD, and other senior staff. NIA has supported kidneyrelated initiatives on acute kidney injury, organ donation, and renal function in older Americans. NIA has also supported initiatives to advance research on multiple chronic conditions such as the request for applications on "Behavioral Interventions to Address Multiple Chronic Health Conditions in Primary Care." ASN encouraged the institute to also consider initiatives in other



areas where there has been little study, such as best management practices for older Americans nearing ESRD and kidney–mineral bone disorders.

Patient-Centered Outcomes Research Institute (PCORI)

ASN met with PCORI Chief Science Officer Bryan Luce, PhD, and other senior staff. PCORI is a new institute with a relatively small research grant portfolio and has provided more than \$16 million in grants for kidney-related projects to date. PCORI recently announced a joint collaboration with NHLBI on a comparative effectiveness research initiative to study how to reduce disparities in treating hypertension. The initiative is only the second PCORI–NIH collaboration. The first was for a study on falls among the elderly with NIH. ASN encouraged PCORI and NHLBI to consider kidney disease phenotypes given the significant association between the two.

Kidney Research Advocacy Day Participants

- Frank C. Brosius, III, MD, University of Michigan Hospital
- Josef Coresh, MD, PhD, FASN, Welch Center for Prevention, Epidemiology & Clinical Research
- Deidra C. Crews, MD, FASN, Johns Hopkins University School of Medicine William Fissell, MD, Vanderbilt University
- Edgar A. Jaimes, MD, Memorial Sloan-Kettering Cancer Center
- Jordan A. Kreidberg, MD, PhD, Children's Hospital Boston
- Jeffrey H. Miner, PhD, Washington University Renal Division
- John R. Sedor, MD, FASN, MetroHealth Medical Center
- Mark L. Unruh, MD, University of New Mexico
- Tushar J. Vachharajani, MD, FASN, W.G. (Bill) Hefner VA Medical Center

Efforts to Address Health Disparities: A Multipronged Approach

By Rachel Meyer

In many ways, kidney disease is the poster child for health disparities in the United States. In 2012, African Americans were nearly four times as likely and Native Americans nearly twice as likely as whites to experience kidney failure (1). African Americans, Hispanics, Native Americans, and Alaska Natives are twice as likely as whites to have diabetes, the leading cause of kidney disease. The incidence of ESRD in people with diabetes is six times as high in Native Americans compared with the incidence in the general population of diabetes patients. Moreover, minority populations spend more time on the wait list for a kidney transplant and are less likely to utilize a home dialysis modality (2).

Addressing these health disparities was a top ASN Public Policy priority in 2014, and in 2015 the society will continue to prioritize efforts at the federal legislative, regulatory, and profession-sanctioned levels to

Efforts to Address Health Disparities

minorities in all comment letters.

raise awareness and reduce disparities. Table 1 depicts ASN's efforts to integrate health disparities advocacy into every aspect of the society's 2014 policy priorities. ASN endeavors to ensure that Congress, federal research funding agencies, and Medicare are aware of these discrepancies and take every opportunity to confront them on behalf of the millions of Americans who are at disproportionate risk for kidney disease or compromised access to kidney care.

Table 1. 2014 ASN Policy Efforts to Address Health Disparities

2014 ASN Public Policy Priorities

- 1. Influence the evolution of the ESRD Quality Incentive Program and participate, in collaboration with the entire kidney community, in the bundle rebasing process.
- 2. Shape the implementation and evaluation of the ESRD Seamless Care Organization (ESCO) program.
- 3. Develop and implement a long-range strategic plan regarding interactions with NIH and NIDDK, and continue to expand ASN's research advocacy beyond NIH.
- 4. Collaborate with other stakeholder coalitions to ensure a successful launch of the NIDDK Coalition.
- Promote recognition of Kidney Health Initiative (KHI) within FDA and Congress, and begin to develop policy positions on legislation related to the FDA.
- 6. Foster the interest of younger and more diverse nephrologists in public policy issues, including establishing a policy track at Kidney Week.
- 7. Identify potential legislative or regulatory strategies to address the declining interest in nephrology careers.

Advocated for strong oversight to prevent cherry-picking of vulnerable patient populations.
Emphasized need for vigilance regarding equitable access to transplant.
Promoted health disparities research among and collaboration between federal research agencies

· Highlighted effects of proposed changes to the ESRD bundle and QIP on underrepresented

Promoted the need for providers and practices of all sizes and types, serving all patient

populations and geographic regions, to be able to participate in the ESCO program.

Encouraged development and selection of QIP measures and risk-adjustment strategies that properly account for the unique needs and characteristics of underrepresented minorities.

- Promoted health disparities research among and collaboration between federal research agencies and programs as ASN's key research recommendation, including NIH and the VA's research office,
 Asked the GAO to specifically assess gaps in health disparities research as part of GAO's
- assessment of the overall federal investment in kidney research funding.
- Advocated that the Friends of the NIDDK join ASN in emphasizing the importance of disparities research as a crucial, cross-cutting area in all interactions with NIDDK.
- Highlighted the fact that significant health disparities exist in kidney disease as an important reason to promote innovative technologies and therapies that could potentially help reduce inequities in risk, diagnosis, and care of underrepresented minorities.
- Ensure diversity in terms of speaker and moderator selection in public policy sessions.

9/1/2014 Average No. Cop Each Issue Durin Preceding 12 Mo 19371

17424

0

818

0

18242

0
0
0

0

0

18242

1129

19371

100.00%

18546

17609

0

819

0

18428

0

0

0

0

18428

118


18546

100.00%

Explored developing federal loan repayment programs that support underrepresented minorities
Encouraged federal funding agencies, especially NIMHD and NIDDK, to continue to expand programs that specifically fund underrepresented minorities

- 1. USRDS, 2014.
- 2. DPC Education Center. http://dpcedcenter.org/kidney-health-disparities

DUNITED STATES Statement of POSTAL SERVICE (All Periodicals Period	f Ownership, Manageme ublications Except Require 12. Publication Number	uester Publications)	13.	Publication Titl	Ā	SN Kidney News
ASN Kidney News	2. Publication Number 1 9 4 3 8 0 4 4 5. Number of Issues Published Annually		15.	5. Extent and Nature of Circulation		
Monthly	12	6. Annual Subscription Price 12.00		a. Total Number of Copies (Net press run)		
Complete Mailing Address of Known Office of Publication (Not printer) (St American Society of Nephrology 1510 H Street NW #800 Microbiostore DC 09005	eet, city, county, state, and ZIP+4®)	Contact Person Bob Henkel Telephone (Include area code)			(1)	Mailed Outside-County Paid Subscriptions Stated on PS Form 3541 (In distribution above nominal rate, advertiser's proof copies, and exchange
Washington DC 20005 Complete Mailing Address of Headquarters or General Business Office of Publisher (<i>Not printer</i>)		202-557-8360	b. Paid Circulation (By Mail		(2)	Mailed In-County Paid Subscriptions Stated on PS Form 3541 (Include distribution above nominal rate, advertiser's proof copies, and exchange
American Society of Nephrology 1510 H Street NW #800 Washington DC 2000		05	and Outside the Mail)	(3)	Paid Distribution Outside the Mails Including Sales Through Dealers and Street Vendors, Counter Sales, and Other Paid Distribution Outside USF	
 Full Names and Complete Mailing Addresses of Publisher, Editor, and Managing Editor (Do not leave blank) Publisher (Name and complete mailing address) 				(4)	Paid Distribution by Other Classes of Mail Through the USPS (e.g., First-Class Mail®)	
American Society of Nephrology 1510 H Street NW #800 Washington DC 20005		05		c. Total Paid D	Nistrii	bution [Sum of 15b (1), (2), (3), and (4)]
ditor (Name and complete mailing address)				d. Free or	(1)	Free or Nominal Rate Outside-County Copies included on PS Form 35
Pacale Lane, MD, Oklahoma University, 1200 North Phillips, Suite 14200, Oklahoma City		y OK 73104		Nominal Rate	(1)	
Nanaging Editor (Name and complete mailing address)				Distribution (By Mail and	(2)	Free or Nominal Rate In-County Copies Included on PS Form 3541
Dawn McCoy, 2016 Lonacera Way Charlottesville, VA 22911				Outside the Mail)	(3)	Free or Nominal Rate Copies Mailed at Other Classes Through the US (e.g., First-Class Mail)
0. Owner (Do not leave blank. If the publication is owned by a corporation, give the name and address of the corporation names and addresses of all atockholders owning or holding 1 percent or more of the total amount of stock. If not owne names and addresses of the individual owners. If owned by a patheraphi or other unincorporated firm, give its name and addresses of the individual owners. If owned by a patheraphi or other molecular data and a stock is not owner.		ed by a corporation, give the			(4)	Free or Nominal Rate Distribution Outside the Mail (Carriers or other n
each individual owner. If the publication is published by a nonprofit organ full Name	ation, give its name and address.) Complete Mailing Address			e. Total Free or Nominal Rate Distribution (Sum of 15d (1), (2), (3) and (4))		
American Society of Nephrology	Tod Ibrahim			f. Total Distribution (Sum of 15c and 15e)		
	Executive Director					
	1510 H St N			s not Distributed (See Instructions to Publishers #4 (page #3)) (Sum of 16f and g)		
	Washington I					
				i. Percent Paid (15c divided by 15f times 100)		
1. Known Bondholders, Mortgagees, and Other Security Holders Owning o Other Securities. If none, check box	Holding 1 Percent or More of Total Amount	t of Bonds, Mortgages, or	• If y	ou are claimin	g ele	ectronic copies, go to line 16 on page 3. If you are not claiming electronic
full Name	Complete Mailing Address					
	1					



Don't miss the January Kidney News predictions for top issues to watch in the new year.

Classified Ads

PRINT ADVERTISING THE EFFECTIVE WAY TO:

GROW YOUR WORKFORCE

INVEST IN YOUR FUTURE WITH FELLOWSHIPS

FURTHER YOUR EDUCATION WITH CME COURSES

PROMOTE AN UPCOMING CONFERENCE

These plus more opportunities available when you contact

Rhonda Truitt rhonda.truitt@wt-group.com 443-512-8899 x 106

Kidney News Classified Advertising Information

Classified space is for advertising positions available, open faculty positions, course announcements, seminars, meetings and educational courses.

Display Advertising Rates						
Ad Size	1x	3x				
Full Page	\$2,525	\$2,345				
1/2 Page	\$1,665	\$1,485				
1/3 Page	\$1,435	\$1,375				
1/4 Page	\$1,205	\$1,090				
1/6 Page	\$1,035	\$1,025				

Line Advertising Rates

Please contact for rate information

Closing Date & Cancellations:

Copy must be received four weeks in advance of the month in which the ad is to appear. Cancellation requests must be made in written form by fax, e-mail or postal mail and will be honored for the earliest applicable issue.

All Ads Must be Prepaid

Contact: Rhonda Truitt rhonda.truitt@wt-group.com P: 443-512-8899 x. 106 F: 443-512-8909

ASN Highlights US

Translating Kidney Week into Clinical Practice

ASN Highlights is a clinically focused educational opportunity, translating Kidney Week 2014 into practical advice with clinical relevance. The new ASN Highlights format is designed to help you incorporate the best of Kidney Week into patient care.

General Nephrology & CKD

Glomerular Diseases

Topics Include:

Hypertension

Transplantation

• AKI

ESRD

Why Attend?

- 7.5 CME credits
- Meet-the-Expert
- Roundtables

 Panel Discussions &
- Debates

 Networking with local
- colleagues

www.asn-online.org/highlights

Three locations; same great content: Chicago, IL

Friday, February 13 (full day) Houston, TX

Friday, February 20 (full day) Orlando, FL

Friday, February 27 & Saturday, February 28 (half days)



Index to Advertisers

ASN

Amgen	Page 7
CryoLife	Page 2
Otsuka	ck Page

SAMSCA® (tolvaptan) tablets for oral use

WARNING: INITIATE AND RE-INITIATE IN A HOSPITAL AND MONITOR SERUM SODIUM

SAMSCA should be initiated and re-initiated in patients only in a hospital where serum sodium can be monitored closely. Too rapid correction of hyponatremia (e.g., >12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma and death. In susceptible patients, including those with severe mainutrition, alcoholism or advanced liver disease, slower rates of correction may be advisable INDICATIONS AND USAGE: SAMSCA is indicated for the treatment of clinically significant hypervolemic and euvolemi isted correction with fluid

hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted restriction), including patients with heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH). Important Limitations: Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with SAMSCA. It has not been established that raising serum sodium with SAMSCA provides a

matic benefit to patients

CONTRAINDICATIONS: SAMSCA is contraindicated in the following conditions: Urgent need to raise serum sodium acutely: SAMSCA has not been studied in a setting of urgent need to raise serum sodium

CONTRAINDICATIONS: SAMSCA is contraindicated in the following conditions: Urgent need to raise serum sodium acutely: SAMSCA has not been studied in a setting of urgent need to raise serum sodium acutely. Inability of the patient to sense or appropriately respond to thirst: Patients who are unable to auto-regulate fluid balance are at substantially increased risk of incurring an overly rapid correction of serum sodium, hypernatrenia and hypovolemia. Hypovolemic hyponatremia: Risks associated with worsening hypovolemia, including complications such as hypotension and renal failure, outweigh possible benefits. Concomitant use of strong CYP 3A inhibitors: Ketoconazole 200 mg administered with tolvaptan increased tolvaptan exposure by 5-fold. Larger doses would be expected to produce larger increases in tolvaptan exposure. There is not adequate experience to define the dose adjustment that would be needed to allow safe use of tolvaptan with strong CYP 3A inhibitors such as clarithromycin, ketoconazole, itraconazole, ritonavir, indinavir, neffinavir, saquinavir, nefazodone, and telithromycin. Anuric patients: in patients unable to make urine, no clinical benefit can be expected. Hypersensitivity: SAMSCA is contraindicated in patients with hypersensitivity (e.g. anaphylactic shock, rash generalized) to tolvaptan or any component of the product [see Adverse Reactions (6.2)]. WARNINGS AND PRECAUTIONS: Too Rapid Correction of Serum Sodium Can Cause Serious Neurologic Sequelae (see BOXED WARNING): Osmotic

WARNINGS AND PRECAUTIONS: Too Rapid Correction of Serum Sodium Can Cause Serious Neurologic Sequelae (see BOXED WARNING): Osmotic demyelination syndrome is a risk associated with too rapid correction of hyponatremia (e.g., >12 mEq/L/24 hours). Osmotic demyelination results in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma or death. In susceptible patients including those with severe malnutrition, alcoholism or advanced liver disease, slower rates of correction may be advisable. In controlled clinical trials in which tolvaptan was administered in titrated doses starting at 15 mg once daily, 7% of be advisable. In controlled clinical trials in which tolvaptan was administered in Itrated doses starting at 15 mg once daily, 7% of tolvaptan-treated subjects with a serum sodium <130 mEq/L had an increase greater than 12 mEq/L at 24 hours. Approximately 1% of placebo-treated subjects with a serum sodium <130 mEq/L had an increase greater than 12 mEq/L at 24 hours. Approximately 1% of placebo-treated subjects with a serum sodium <130 mEq/L had a rise greater than 8 mEq/L at 8 hours and no patient had a rise greater than 12 mEq/L/24 hours. Osmotic demyelination syndrome has been reported in association with SAMSCA therapy *[see Adverse Reactions (6.2)]*. Patients treated with SAMSCA should be monitored to assess serum sodium concentrations and neurologic status, especially during initiation and after titration. Subjects with SIADH or very low baseline serum sodium concentrations may be at greater risk for too-rapid correction of serum sodium. In patients receiving SAMSCA who develop too rapid a rise in serum sodium, discontinue or interrupt treatment with SAMSCA and consider administration of hypotonic fluid. Fluid restriction during the first 24 hours. AdMSCA may increase the likelihood of overly-rapid correction of serum sodium, and should generally be avoided. Liver Injury: SAMSCA can cause serious and potentially fatal liver injury. In a placebo-controlled and open label extension study of chronically administered tolvaptan in patients with autosomal dominant polycystic kidney disease, cases of serious liver injury attributed to tolvaptan were observed. An increased incidence of ALT orcurred prior to 3 months. Patients with symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundicae should discontinue treatment with SAMSCA. Liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundicae should discontinue treatment with SAMSCA. Liver injury, including fatigue, anorexia, right upper abdominal discomfort, tolvaptan-treated subjects with a serum sodium <130 mEq/L had an increase in serum sodium greater than 8 mEq/L at approximately

Drug Interactions

Drug Interactions: Other Drugs Affecting Exposure to Tolvaptan: CYP 3A Inhibitors: Tolvaptan is a substrate of CYP 3A. CYP 3A inhibitors can lead to a marked increase in tolvaptan concentrations [see Dosage and Administration (2.3), Drug Interactions (7.1)]. Do not use SAMSCA with strong inhibitors of CYP 3A [see Contraindications (4.4)] and avoid concomitant use with moderate

CYP 3A inhibitors. CYP 3A inducers: Avoid co-administration of CYP 3A inducers (e.g., rifampin, rifabutin, rifapentin, barbiturates, phenytoin, carbamazepine, St. John's Wort) with SAMSCA, as this can lead to a reduction in the plasma concentration of tolvaptan and decreased effectiveness of SAMSCA treatment. If co-administered with CYP 3A inducers, the dose of SAMSCA may need to be increased [see Dosage and Administration (2.3), Drug Interactions (7.1)]. P-gp Inhibitors: The dose of SAMSCA may have to be reduced when SAMSCA is co-administered with P-gp inhibitors, e.g., cyclosporine [see Dosage and Administration (2.3), Drug Interactions (7.1)]. Hyperkalemia or Drugs that Increase Serum Potassium: Treatment with tolvaptan is associated with an acute reduction of the extracellular fluid volume which could result in increased serum potassium. Serum potassium levels should be monitored after initiation of tolvaptan treatment in patients with a serum potassium >5 mEq/L as well as those who are receiving drugs known to increase serum potassium levels. ium levels

ADVERSE REACTIONS

Increase serum potassium levels. **ADVERSE REACTIONS: Clinical Trials Experience:** Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse event information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates. In multiple-dose, placebo-controlled trials, 607 hyponatremic patients (serum sodium <135 mEq/L) were treated with SAMSCA. The mean age of these patients was 62 years; 70% of patients were male and 82% were Caucasian. One hundred eighty nine (189) tolvaptan-treated patients had a serum sodium <130 mEq/L, and 52 patients had a serum sodium <125 mEq/L. Hyponatremia was attributed to cirrhosis in 17% of patients, heart failure in 68% and SIADH/other in 16%. Of these patients, 223 were treated with the recommended dose titration (15 mg titrated to 60 mg as needed to raise serum sodium). Overall, over 4,000 patients have been treated with oral doses of tolvaptan in open-label or placebo-controlled dinical trials. Approximately 650 of these patients had hyponatremia; approximately 219 of these hyponatremic patients were treated with tolvaptan for 6 months or more. The most common adverse reactions (incidence ≥5% more than placebo) seen in two 30-day, double-blind, placebo-controlled hyponatremia trials in which tolvaptan was administered in threade to 80 mg once daily) were thirst, dy mouth, asthenia, constipation, pollakiuria or polyuria and hyperglycemia. In these trials, 10% (23/223) of tolvaptan-treated patients discontinued treatment because of an adverse event, compared to 12% (26/220) of placebo-treated patients; no adverse reaction resulting in discontinuation of trial medication occurred at an incidence of >1% in tolvaptan-treated patients. Table 1 lists the adverse

Table 1. Adverse Reactions (>2% more than placebo) in Tolvaptan-Treated Patients in Double-Blind, Placebo Hyponatremia Trials

System Organ Class MedDRA Preferred Term	Tolvaptan 15 mg/day-60 mg/day (N = 223) n.(%)	Placebo (N = 220) n (%)	
Gastrointestinal Disorders			
Dry mouth	28 (13)	9 (4)	
Constipation	16 (7)	4 (2)	
General Disorders and Administration Site Co	nditions		
Thirst ^a	35 (16)	11 (5)	
Asthenia	19 (9)	9 (4)	
Pyrexia	9 (4)	2 (1)	
Metabolism and Nutrition Disorders			
Hyperglycemia ^b	14 (6)	2 (1)	
Anorexia	8 (4)	2 (1)	
Renal and Urinary Disorders	· · · · ·		
Pollakiuria or polyuriad	25 (11)	7 (3)	

The following terms are subsumed under the referenced ADR in Table 1: ^apolydipsia; ^bdiabetes mellitus; ^cdecreased appetite; ^durine output increased, micturition, urgency, nocturia

In a subgroup of patients with hyponatremia (N = 475, serum sodium <135 mEg/L) enrolled in a double-blind, placebo-controlled in a long op platent in the platent platent was platent with worsening heart failure, the following adverse reactions occurred in tolvaptan-treated patients at a rate at least 2% greater than placebo: mortality (42% tolvaptan, 38% placebo), nausea (21% tolvaptan, 16% placebo), thirst (12% tolvaptan, 2% placebo), dry mouth (7% tolvaptan, 2% placebo) and polyuria or pollakiuria (4% tolvaptan, 1% placebo).

Gastrointestinal bleeding in patients with cirrhosis: In patients with cirrhosis treated with tolvaptan in the hyponatremia trials, gastrointestinal bleeding was reported in 6 out of 63 (10%) tolvaptan-treated patients and 1 out of 57 (2%) placebo treated patients. The following adverse reactions occurred in <2% of hyponatremic patients treated with SAMSCA and at a rate greater than placebo in double-bindiplacebo-controlled trials (N = 60 Tolvaptan, N = 51 & placebo) in <2% of placebo, price in <2% of hyponatremic patients in an uncontrolled trial of patients with hyponatremia (N = 111) and are not mentioned elsewhere in the label: *Blood and Lymphatic System Disorders: Disseminated intravascular cogulation; Cardiac Disorders: Intravarbic System Torrbursus truncationals investiges and the provinges of astrointestinal Disorders: Rhadomyolysis; Nervus System: Certovascular accident; Renal and Urinary Disorders: Uratinal hemorrhage; Respiratory, Altrony yesing Vaster Vascular disorder: Deep vein thromhosis. Postmarketing Experience: The following adverse reactions have been identified during post-approval use of SAMSCA. Because these reactions are reported voluntarily from a population of an unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Neurologic: Cosmolic demyeliantion synchrom; Investigations: Hypernatremia, Removal of excess free body water increases serum osmolatily and serum sodium concentrations. All patients treated with tolvaptan, respecially those whose serum sodium levels become normal, should continue to be monitored to ensure serum social treatment, combined with modification of free-water inflasion. During clinical triads of Hyponatremic patients: necesiving placebo. Immune System Disorders: Hyperenatremia to a reported as an adverse prevent in 0.7% of patients receiving placebo, analysis of laboratory values demonstrated an incidence of hypenatreming of 1.7% in patients receiving placebo, analysis of laboratory value*

factors of 1.4 and 1.3, respectively. This is not a clinically relevant change. Pharmacodynamic Interactions: Tolvaptan produces a greater 24 hour urine volume/excretion rate than does furosemide or hydrochlorothiazide. Concomitant administration of tolvaptan with furosemide or hydrochlorothiazide results in a 24 hour urine volume/excretion rate that is similar to the rate after tolvaptan administration alone. Although specific interaction studies were not performed, in clinical studies tolvaptan was used concomitantly with beta-blockers, angiotensin receptor blockers, angiotensin converting enzyme inhibitors and potassium sparing diuretics. Adverse reactions of hyperkalemia were approximately 1-2% higher when tolvaptan was administered with angiotensin receptor blockers, angiotensin converting enzyme inhibitors and potassium sparing diuretics. Adverse reactions on hyperkalemia were approximately 1-2-6 higher sparing diuretics compared to administration of these medications with placebo. Serum potassium levels should be monitored during concomitant drug therapy. As a v_2 receptor antagonist, tolvaptan may interfere with the V_2 agonist activity of desmopressin (dDAVP). In a male subject with mild Von Willebrand (WV) disease, intravenous infusion of dDAVP 2 hours after administration of oral tolvaptan did not produce the expected increases in vW Factor Antigen or Factor VIII activity. It is not recommended to

administer SAMSCA with V₂ agonist. USE IN SPECIFIC POPULATIONS: There is no need to adjust dose based on age, gender, race, or cardiac function [see Clinical acology (12.3)].

Pregnancy: Pregnancy Category C. There are no adequate and well controlled studies of SAMSCA use in pregnant women. In animal studies, cleft palate, brachymelia, microphthalmia, skeletal malformations, decreased fetal weight, delayed fetal ossification, and embryo-fetal death occurred. SAMSCA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In embryo-fetal development studies, pregnant rats and rabbits received oral tolvaptan during organogenesis. Rats received 2 to 162 times the maximum recommended human dose (MRHD) of tolvaptan (on a body surface area basis). Reduced received 2 to 1o2 times the maximum recommended human dose (MRHD) of tovaptan (on a body surface area basis). Reduced fetal weights and delayed fetal ossification occurred at 162 times the MRHD. Signs of maternal toxicity (reduction in body weight gain and food consumption) occurred at 16 and 162 times the MRHD. When pregnant rabbits received oral tolvaptan at 32 to 324 times the MRHD (on a body surface area basis), there were reductions in maternal body weight gain and food consumption at all doses, and increased abortions at the mid and high doses (about 97 and 324 times the MRHD). At 324 times the MRHD, there were increased rates of embryo-fetal death, fetal microphthalmia, open eyelids, cleft palate, brachymelia and skeletal malformations (see Mondinical Toxicology (13.31)

[see Nonclinical Toxicology (13.3)]. Labor and Delivery: The effect of SAMSCA on labor and delivery in humans is unknown. Nursing Mothers: It is not known whether SAMSCA is excreted into human milk. Tolvaptan is excreted into the milk of lactating rats. Because many drugs are excreted into human milk and because of the potential for serious adverse reactions in nursing infants from SAMSCA, a decision should be made to discontinue nursing or SAMSCA, taking into consideration the importance of SAMSCA to the mother. SAMSCA to the moth

rats. Because many drugs are excreted into human milk and because of the potential for serious adverse reactions in nursing infants from SAMSCA, a decision should be made to discontinue nursing or SAMSCA, taking into consideration the importance of SAMSCA to the mother. Pediatric Use: Safety and effectiveness of SAMSCA in pediatric patients have not been established. Geriatric Use: Of the total number of hyponatremic subjects treated with SAMSCA in clinical studies, 42% were 65 and over, while 19% were 75 and over. No overall differences in safety or effectiveness were observed between thees subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Increasing age has no effect on tolvaptan plasma concentrations. Use in Patients with Patic Impairment: Moderate and severe hepatic impairment do not affect exposure to tolvaptan to a clinically relevant extent. No dose adjustment is necessary. Avoid use of tolvaptan in patients with underlying liver disease. Use in Patients with CrCI < 10 mL/min is not recommended. No benefit can be expected in patients who are anuric *[see Contraindications 4.6]* and *Clinical Pharmacology* (12.3)]. Use in Patients with CrCI < 10 mL/min is not recommended. No benefit can be expected in patients who are anuric *[see Contraindications 4.6]* and *Clinical Pharmacology* (12.3)]. Use in Patients with Congestive Heart Failure: The exposure to tolvaptan in patients with congestive heart failure is not specific antidote for tolvaptan intoxication. The signs and symptoms of an acute overdose can be anticipated to be those of excessive pharmacology cleft: a rise in serum sodium concentration, polyuria, thirst, and dehydration/hypovolemia. The oral LD50 of tolvaptan in rats and dogs is >2000 mg/kg, No mortality was observed in trats or dogs following single oral doses of 2000 mg/kg (maximum feasible dose). A single oral

Interactions (7.1)]. Nursing: Advise patients not to breastfeed an infant if they are taking SAMSCA [see Use In Specific Populations (8.3)]. For more information about SAMSCA, call 1-877-726-7220 or go to www.samsca.com. Manufactured by Otsuka Pharmaceutical Co., Ltd., Tokyo, 101-8535 Japan Distributed and medicated by Otsuka Pharmaceutical Co., Bergerson and States Inc. (2005).

Samual and marked by Otsuka Priamaceutical Co., Ltd., Tokyo, To Posso Japan Distributed and marked by Otsuka America Pharmaceutical, Inc., Rockville, MD 20850 SAMSCA is a registered trademark of Otsuka Pharmaceutical Co., Ltd., Tokyo, 101-8535 Japan





Otsuka America Pharmaceutical, Inc. © 2014 Otsuka Pharmaceutical Co., Ltd.

07US14L-0919B Rev. 02, 2014

For Clinically Significant Hypervolemic and Euvolemic Hyponatremia: Serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction

WHEN FLUID RESTRICTION IS NOT ENOUGH, HELP PATIENTS BREAK FREE WITH FREE WATER CLEARANCE



Too rapid correction of serum sodium can cause serious neurologic sequelae
 Avoid fluid restriction during the first 24 hours of therapy

INDICATION and Important Limitations

- SAMSCA is indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH)
- Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with SAMSCA. It has not been established that raising serum sodium with SAMSCA provides a symptomatic benefit to patients

IMPORTANT SAFETY INFORMATION

SAMSCA should be initiated and re-initiated in patients only in a hospital where serum sodium can be monitored closely. Too rapid correction of hyponatremia (e.g., >12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma and death. In susceptible patients, including those with severe malnutrition, alcoholism or advanced liver disease, slower rates of correction may be advisable

Contraindications: Urgent need to raise serum sodium acutely, inability of the patient to sense or appropriately respond to thirst, hypovolemic hyponatremia, concomitant use of strong CYP 3A inhibitors, anuric patients, and hypersensitivity (e.g. anaphylactic shock, rash generalized) to tolvaptan or its components **Warnings and Precautions:**

- Subjects with SIADH or very low baseline serum sodium concentrations may be at greater risk for too-rapid correction of serum sodium. In patients receiving SAMSCA who develop too rapid a rise in serum sodium or develop neurologic sequelae, discontinue or interrupt treatment with SAMSCA and consider administration of hypotonic fluid. Fluid restriction should generally be avoided during the first 24 hours
- SAMSCA can cause serious and potentially fatal liver injury. Avoid use in patients with underlying liver disease, including cirrhosis, because the ability to recover may be impaired. Limit duration of therapy with SAMSCA to 30 days
- Dehydration and hypovolemia can occur, especially in potentially volume-depleted patients receiving diuretics or those who are fluid restricted. In patients who develop medically significant signs or symptoms of hypovolemia, discontinuation is recommended
- Co-administration with hypertonic saline is not recommended
- Avoid concomitant use with: CYP 3A inhibitors and CYP 3A inducers. The dose of SAMSCA may have to be reduced if co-administered with P-gp inhibitors
 Monitor serum potassium levels in patients with a serum potassium >5 mEq/L and in patients receiving drugs known to increase serum potassium levels
 Adverse Reactions The most common adverse reactions (SAMSCA incidence ≥5% more than placebo, respectively): thirst (16% vs 5%), dry mouth (13% vs 4%), asthenia (9% vs 4%), constipation (7% vs 2%), pollakiuria or polyuria (11% vs 3%) and hyperglycemia (6% vs 1%)

Gastrointestinal Bleeding in Patients with Cirrhosis – In patients with cirrhosis in the hyponatremia trials, Gl bleeding was reported in 10% of tolvaptantreated patients vs 2% for placebo

Please see Brief Summary of FULL PRESCRIBING INFORMATION, including Boxed WARNING, on following page.

Manufactured by Otsuka Pharmaceutical Co., Ltd., Tokyo, 101-8535 Japan. Distributed and marketed by Otsuka America Pharmaceutical, Inc., Rockville, MD 20850. SAMSCA is a registered trademark of Otsuka Pharmaceutical Co., Ltd., Tokyo, 101-8535 Japan.

For more information please visit SAMSCA.com

Otsuka Otsuka America Pharmaceutical, Inc.

©2014 Otsuka America Pharmaceutical, Inc.

June 2014